Last reviewed · How we verify

NCT04072120

Stroke Survival in Municipalities: Impact of Geographic Proximity to First- and Second-degree Relatives

Status unknown Last updated 15 May 2020
What this trial tests

trial in Stroke in 7,400,000 participants. Status unknown.

Timeline
15 August 2019
Primary endpoint
14 August 2022
14 August 2022

Quick facts

Lead sponsorUniversity of Oslo
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment7,400,000
Start date15 August 2019
Primary completion14 August 2022
Estimated completion14 August 2022
Sites1 location across Norway

Conditions studied

Sponsor

University of Oslo

Who can join

45 and older, any sex, with Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Our key objective will be to investigate if geographic proximity to first- and second-degree relatives has an influence on post-acute stroke survival and use of health and social services. We will also model and map spatial variation in stroke and cardiovascular disease (CVD) incidence and mortality and see if some of the variation is due to spatial clustering of familial risk. The study will use innovative approaches to large-scale registry and survey data and statistical analysis on the full Norwegian population. We will integrate multigenerational and geographical information. This will enable us to assess key determinants on stroke survival and use of health and social care at municipality level.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Stroke

Currently open trials in the same condition.

Other University of Oslo trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04072120.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing